LABS seems like a no brainer heading into 2024Several catalysts beyond Medipharm’s control that could add a bump to the share price near term
ANVISA approvals
Canadian Federal excise tax cuts
DEA rescheduling announcement
Generic Epidiolex announcements
Any of the current ongoing Trial updates
Increased global Dronbinol orders in first quarter
Reveal of Medipharm’s international partner
Reputable Global Analyst coverage
Q1 improvements to bottom line
Take over announcement